Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 8/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5008769 | 0.84 | MAPK14 (0.49) | BRAFCDK8MAPK14MAPK12MAPK13 | |
| SCHEMBL5008440 | 0.80 | MAPK14 (0.45) | CDK8MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL5008388 | 0.78 | MAPK14 (0.53) | BRAFMAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL5005312 | 0.75 | MAPK14 (0.51) | MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL5008529 | 0.75 | MAPK14 (0.59) | CDK8MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL5005583 | 0.74 | GFER (0.53) | MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL14600246 | 0.73 | MAPK13 (0.53) | BRAFCDK8MAPK14MAPK12MAPK13 | |
| SCHEMBL5010626 | 0.72 | MAPK14 (0.61) | MAPK14MAPK12MAPK13MAPK11 | |
| SCHEMBL5011989 | 0.71 | MAPK14 (0.61) | BRAFCDK8MAPK14MAPK12MAPK13 | |
| SCHEMBL3974140 | 0.71 | MAPK14 (0.46) | CDK8MAPK14MAPK12MAPK13MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-03-13 | — | — | US | disclosed |
| US-7265144-B2 | Anilinopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064734-A1 | Anilinopyrazole derivatives useful for the treatment of diabetes | IAPP, GLP1R, GPR119 | BRAF 2016/4885CDK8 1684/4885MAPK14 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.